In the Media: Dr. Juliet Emamaullee on Liver Cancer Risk Not Increased with Pre-Transplant Antiviral
Direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection prior to liver transplant does not increase pre-transplant liver cancer progression or post-transplant recurrence, according to a new study of both waitlist patients and liver transplant (LT) recipients. The investigators characterized the study as one of the first examinations of the impact of DAA treatment on liver transplant recipients with hepatocellular carcinoma (HCC), both pre- and post-LT.
Juliet Emamaullee, MD, PhD, who was in the Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, Canada, at the time of the study, explained how this investigation helped resolve speculation over whether DAA treatment contributes to HCC, in discussion with MD Magazine®. Click here for the entire article.